Adaptive immunity company heads for next phase.
Novel degrader programmes in oncology and inflammatory diseases head for preclinical development.
Results to 30 June, 2024 reveal a strengthened balance sheet.
First Phase 2 clinical trial as FDA approval sought.
Next Cambridge meet-up is 18 September.
Find out who triumphed in the annual awards, held on the Wellcome Genome Campus.
University of Cambridge, Wellcome Sanger Institute and EMBL-EBI to team up.
It now has a 44 per cent stake in the clinical-stage biotechnology company.
Cambridge, Oxford and Caltech researchers have tested it in mice so far.
Neuroscience technologies to assess cognitive function go global.
Helping to grow the sector with access to career opportunities.
New president is seasoned Danaher executive.
World’s fastest chip-based cell sorting tool now available for installation.
Synthetic biology start-up acts on tumours without affecting healthy tissues.